Abbott sales dip in Q3 due to COVID testing sales declines, infant formula manufacturing stoppage

Abbott’s sales in Q3 totaled $10.4 billion, marking a decrease of 4.7%, though the company once again raised its full-year guidance.

The dip in the company’s sales were due in part to declines in COVID-19 testing-related sales and an abrupt infant formula production stoppage at one of its manufacturing plants earlier this year.